Metraipolis › archive › dc_a611d51f2a4e

Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates — Europe PMC PMID:41822315

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41822315
DOI
10.14740/wjon2718
License (as archived)
solo-consultazione
Archived
2026-11-05T02:39:09.678Z
SHA-256 of the archived text
958a807ec2ab4730890177fb0db5783e44448a6fb3aeae2ce98a52f4d66cd94f
Stable URL of this page
https://metraipolis.com/documento/dc_a611d51f2a4e

How to cite

Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates — Europe PMC PMID:41822315 — Europe PMC (en), https://europepmc.org/article/MED/41822315 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a611d51f2a4e (Metraipolis archive dc_a611d51f2a4e, sha256 958a807ec2ab4730890177fb0db5783e44448a6fb3aeae2ce98a52f4d66cd94f)
BibTeX
@misc{dca611d51f2a4e,
  title = {Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates — Europe PMC PMID:41822315},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41822315},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a611d51f2a4e; sha256 958a807ec2ab4730890177fb0db5783e44448a6fb3aeae2ce98a52f4d66cd94f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41822315. Agents can read the archived copy with the MCP tool read_document.